Abstract
Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90%. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk-stratified, response-based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors. Pediatr Blood Cancer 2014;61:579-586.
Original language | English (US) |
---|---|
Pages (from-to) | 579-586 |
Number of pages | 8 |
Journal | Pediatric Blood and Cancer |
Volume | 61 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2014 |
Keywords
- Chemotherapy
- Hematopoietic cell transplant
- Hodgkin lymphoma
- Pediatric oncology
- Relapse
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology